DEF: LeMaitre Vascular Schedules 2026 Annual Meeting

LeMaitre Vascular, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation approval, and auditor ratification.

Summary

• LeMaitre Vascular, Inc. is holding its 2026 Annual Meeting of Stockholders on June 2, 2026, at 10:00 a.m. EDT.
• The meeting will cover the election of two Class II directors, an advisory vote on 2025 executive compensation, and the ratification of Grant Thornton LLP as the independent auditor for fiscal year 2026.
• The company is utilizing the 'Notice of Internet Availability of Proxy Materials' to reduce printing and distribution costs and environmental impact.
• The record date for determining stockholders entitled to vote is April 6, 2026.
• Key proposals include electing David B. Roberts and John A. Roush as Class II directors.
• The Board of Directors unanimously recommends voting FOR all proposals.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong reported financial performance in 2025 and a clear, well-structured agenda for the annual meeting, despite minor administrative compliance issues.

Positives

• The company is leveraging electronic delivery of proxy materials, indicating a commitment to cost savings and environmental responsibility.
• The Board of Directors unanimously recommends favorable votes on all proposals, suggesting alignment between management and the board.
• The company highlights its ability to retain top talent, with an average tenure of 23 years for its Named Executive Officers (NEOs) as of December 31, 2025.
• For 2025, the company reported strong financial performance with 14% net sales growth, a 290 bps increase in gross margin, 30% increase in income from operations, 31% increase in net income, and a 30% increase in diluted EPS.
• The annual dividend payment to shareholders was increased by 25% in 2025.

Negatives

• Bridget Ross, a current Class II director, will not stand for re-election, necessitating the election of new directors.
• The filing notes that two Form 4s for Bridget Ross and John Roush were not timely filed in respect of an obligation arising on August 8, 2025, indicating a minor compliance lapse.
• Two covered employees had adjusted compensation exceeding $1 million in 2025, resulting in $4.4 million in non-deductible compensation due to Section 162(m) of the Internal Revenue Code.

Risks

• The company's compensation policies and practices are subject to risk analysis, though management assessed that these risks are not likely to have a material adverse effect.
• The potential for clawbacks of incentive-based compensation exists if the company is required to prepare a financial restatement due to misconduct or material noncompliance.

Future Outlook

The filing does not contain specific forward-looking financial guidance but focuses on the upcoming annual meeting and proposals for stockholder consideration. The company's 2025 financial results indicate strong growth and profitability.

Management Comments

• Your vote is important. In order to ensure your representation at the Annual Meeting, whether or not you plan to attend, please vote your shares by proxy as promptly as possible.
• We have designed our executive compensation program to attract, retain, and motivate highly qualified executives and to align their interests with the interests of our stockholders.
• The Board believes that combining the positions of Chief Executive Officer and Chairman helps to ensure that the Board and management act with a common purpose and provides a single, clear chain of command to execute our strategic initiatives and business plans.

Industry Context

StockSavvy.ai notes that LeMaitre Vascular's strong 2025 financial performance, including double-digit sales growth and improved margins, aligns with positive trends observed in the medical device sector, particularly for companies focused on specialized surgical solutions. The company's focus on director elections and executive compensation is standard for annual meetings, but the robust financial results provide a positive backdrop for these discussions.

Comparison to Industry Standards

• LeMaitre Vascular's 14% net sales growth in 2025 outpaces the average growth rate for many medical device companies, which can vary significantly by sub-sector but often falls in the mid-to-high single digits for established players.
• The reported gross margin of 71.5% is strong and competitive within the medical device industry, where margins can range from 50% to over 80% depending on product complexity and market position.
• The increase in diluted EPS by 30% is a positive indicator of operational efficiency and profitability, generally exceeding industry averages for companies of similar size and maturity.
• The company's peer group TSR (iShares US Medical Devices ETF Index - IHI) shows LeMaitre Vascular's 5-year cumulative TSR is greater than the index, indicating superior performance relative to its industry peers over the longer term.

Management Changes

Corporate Governance

Legal Proceedings

• Two Form 4 filings for Bridget Ross and John Roush were not timely filed in respect of an obligation arising on August 8, 2025.

Related Party Transactions

• No related party transactions requiring disclosure under Item 404(a) of Regulation S-K were disclosed as occurring since January 1, 2025, other than those already disclosed elsewhere in the proxy statement.

Stakeholder Impact

• Shareholders: Will vote on director elections, executive compensation, and auditor ratification. The company's strong financial performance and dividend increase are positive for shareholders.
• Employees: The company's compensation philosophy aims to attract, retain, and motivate talent. A 5% increase in total compensation for employees was approved for 2026.
• Management: Executive compensation is tied to performance, with a significant portion being variable and equity-based, aligning their interests with stockholders.
• Auditors: Grant Thornton LLP is proposed for ratification as the independent registered public accounting firm for fiscal year 2026.

Next Steps

• Stockholders are to vote on the election of directors, approval of executive compensation, and ratification of the independent auditor.
• Final voting results will be published in a Form 8-K within four business days following the Annual Meeting.
• The company will continue to provide proxy materials electronically to many stockholders.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting and does not contain new material financial information or strategic shifts that would warrant a buy or sell recommendation. While the 2025 financial results were strong, this information is historical. The proposals are standard for an annual meeting. Therefore, a 'hold' recommendation is appropriate, pending future operational or strategic updates.

Keywords

LeMaitre Vascular, Proxy Statement, Annual Meeting, DEF 14A, Director Election, Executive Compensation, Auditor Ratification, Stockholder Vote, Corporate Governance